Salvage of a congested DIEAP flap with subcutaneous recombinant tissue plasminogen activator treatment.
Thrombolytic agents are frequently employed in the treatment of thrombosis in combination with early surgical exploration and management. Recombinant tissue plasminogen activator is a second generation thrombolytic agent, which acts specifically at the site of the haemostatic clot with minimal side effects. In this paper, we present a case with venous congestion of the deep inferior epigastric artery perforator (DIEAP) flap, despite a patent anastomosis, in which we achieved a successful outcome with subcutaneous recombinant tissue plasminogen activator treatment.
Ayhan
Suhan
S
Gazi University, Faculty of Medicine, Department of Plastic, Reconstructive and Aesthetic Surgery, Ankara, Turkey. msayhan@gazi.edu.tr
Uygur
Safak
S
Kucukoduk
Ismail
I
Sencan
Ayse
A
D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery; D019074:Epigastric Arteries; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007279:Injections, Subcutaneous; D016462:Mammaplasty / Q000009:adverse effects* / Q000379:methods; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy; D017568:Rectus Abdominis / Q000098:blood supply / Q000637:transplantation; D018570:Risk Assessment; D016879:Salvage Therapy; D013524:Surgical Flaps / Q000098:blood supply*; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator